New Therapy of Laryngeal Papilloma In Children

Overview

This study will determine efficacy of a new and combined treatment of laryngeal recurrent respiratory papillomatosis (RRP), by using a 585 nm pulsed dye laser (PDL) and a dietary supplement, diindolylmethane (DIM). We will compare this new treatment with PDL-only, in a total of 30 children (15 of each treatment), to determine whether this combined treatment would be effective and safe in preventing the RRP recurrence. This is the first study to combine PDL technique with DIM, to develop a new, voice-preserving and long-term effective method of managing laryngeal RRP in children.

Full Title of Study: “Voice Preserving Therapy of Laryngeal Papilloma In Children”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Participant)
  • Study Primary Completion Date: August 2011

Detailed Description

Previous studies have demonstrated that PDL can be used to remove lesions on the vocal cords and elsewhere in the throat causing less damage to surface tissues than other commonly used lasers. In our proposed clinical study, we seek to compare treatment efficacy for RRP by combining PDL with DIM, versus PDL-only treatment, in a total of 30 children with laryngeal papilloma. We will determine whether this combined treatment would be effective and safe in preventing or delaying the RRP recurrence while preserving voice quality. 30 children will be divided randomly into two treatment groups, 15 in each. The experimental group will receive one-time PDL treatment, followed by 3-month oral administration of DIM and an additional 12 months with no treatment. The other group will be treated with PDL-only, as a control, and take a placebo pill for 3 months. All of the patients will be followed for a total of 15 months. We will compare lesion recurrence and laboratory tests between the two groups, to determine efficacy and safety of the new treatment. This is the first study to combine new PDL laser technique with DIM, to develop a new, voice-preserving and long-term effective method of managing laryngeal RRP in children.

Interventions

  • Dietary Supplement: diindolylmethane (DIM)
    • 3-month DIM
  • Device: 585 nm pulsed dye laser
    • once-time PDL

Arms, Groups and Cohorts

  • Experimental: PDL+DIM pill
    • once-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
  • Placebo Comparator: PDL+placebo pill
    • once-time PDL treatment on the lesions, then followed by 3-month oral taking DIM placebo, in other 15 subjects

Clinical Trial Outcome Measures

Primary Measures

  • Number of Cases With Recurrence of Laryngeal Papilloma in 5 Months
    • Time Frame: Recurrence of pailloma at 5 months
    • vocal lesion size and area after 5 month with surgery visible lesion found in >50% of the treated tissue area, after surgery

Secondary Measures

  • Estradiol Level in Blood Pre Treatment
    • Time Frame: Before treatment at baseline
    • determine side-effect by comparing Estradiol level in blood before and after treatment
  • Estradiol Level in Blood Post Treatment
    • Time Frame: 5 month
    • determine side-effect by comparing Estradiol level in blood before and after treatment

Participating in This Clinical Trial

Inclusion Criteria

1. 10 to 21 years of age 2. laryngeal papillomas requiring surgical treatment 3. willingness to participate in the study 4. a signed informed consent form by guardian or parent Exclusion Criteria:

1. age less than 10 year old, or older than 21 year 2. guardian or parent does not understand or can not sign the consent form 3. malignant diseases such as laryngeal cancer 4. history of being hypersensitive to cabbage or other cruciferous vegetables 5. pregnancy

Gender Eligibility: All

Minimum Age: 10 Years

Maximum Age: 21 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Boston University
  • Collaborator
    • National Institute on Deafness and Other Communication Disorders (NIDCD)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Zhi Wang, Professor and Director – Boston University
  • Overall Official(s)
    • Zhi Wang, MD, Principal Investigator, Boston University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.